Skip to main content

Remote Job Finders (RJF)

Memento brings home $93M series A souvenir, picks up bispecific for eye diseases

Memento’s lead asset is a bispecific antibody that blocks VEGF and activates Tie2. The biotech plans to test the candidate in retinal conditions such as neovascular age-related macular degeneration and diabetic macular edema.

Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B

Jazz Pharmaceuticals is diversifying its oncology strategy, orchestrating a new antibody deal with AbCellera that offers $56 million upfront, plus $792 million in biobucks for each of the three initial programs.
Scroll to top